Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
Blood Cancer Journal, Published online: 26 October 2023; doi:10.1038/s41408-023-00933-4Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 26, 2023 Category: Hematology Authors: Ana ïs Schavgoulidze Aurore Perrot Titouan Cazaubiel Xavier Leleu Lydia Montes Caroline Jacquet Karim Belhadj Sabine Brechignac Laurent Frenzel Thomas Chalopin Philippe Rey Jean-Marc Schiano de Collela Mamoun Dib Denis Caillot Margaret Macro Jean Fontan Source Type: research
Reducing the risks of nuclear war—the role of health professionals
Blood Cancer Journal, Published online: 18 October 2023; doi:10.1038/s41408-023-00925-4Reducing the risks of nuclear war—the role of health professionals (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 18, 2023 Category: Hematology Authors: Kamran Abbasi Parveen Ali Virginia Barbour Kirsten Bibbins-Domingo Marcel G. M. Olde Rikkert Richard Horton Robert Mash Carlos Monteiro Elena N. Naumova Eric J. Rubin Peush Sahni James Tumwine Paul Yonga Chris Zielinski Arun Mitra Tilman Ruff Andy Haines Source Type: research
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models
Blood Cancer Journal, Published online: 13 October 2023; doi:10.1038/s41408-023-00930-7Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 13, 2023 Category: Hematology Authors: Jelena Jelicic Karen Juul-Jensen Zoran Bukumiric Michael Roost Clausen Ahmed Ludvigsen Al-Mashhadi Robert Schou Pedersen Christian Bj ørn Poulsen Peter Brown Tarec Christoffer El-Galaly Thomas Stauffer Larsen Source Type: research
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
Blood Cancer Journal, Published online: 13 October 2023; doi:10.1038/s41408-023-00929-0Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 13, 2023 Category: Hematology Authors: Surbhi Sidana Hitomi Hosoya Alexandria Jensen Lawrence Liu Anmol Goyal Vanna Hovanky Bita Sahaf Sushma Bharadwaj Theresa Latchford Sally Arai Sheryl Leahy Matthew Mei Lihua E. Budde Lori S. Muffly Matthew J. Frank Saurabh Dahiya Myo Htut David Miklos Mura Source Type: research
Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
Blood Cancer Journal, Published online: 12 October 2023; doi:10.1038/s41408-023-00927-2Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 12, 2023 Category: Hematology Authors: Preetesh Jain Krystle Nomie Nikita Kotlov VitaIy Segodin Holly Hill Chi Young Ok Ahmed Fetooh Rashmi Kanagal-Shamanna Francisco Vega Alexander Bagaev Nathan Fowler Christopher R. Flowers Michael Wang Source Type: research
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
Blood Cancer Journal, Published online: 11 October 2023; doi:10.1038/s41408-023-00928-1Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 11, 2023 Category: Hematology Authors: Keyuan Zhang Xiang Zhang Yang Xu Shengli Xue Huiying Qiu Xiaowen Tang Yue Han Suning Chen Aining Sun Yanming Zhang Depei Wu Ying Wang Source Type: research
Correction: Zanubrutinib: past, present, and future
Blood Cancer Journal, Published online: 02 October 2023; doi:10.1038/s41408-023-00926-3Correction: Zanubrutinib: past, present, and future (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - October 2, 2023 Category: Hematology Authors: Constantine S. Tam Javier L. Mu ñoz John F. Seymour Stephen Opat Source Type: research
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies
Blood Cancer Journal, Published online: 27 September 2023; doi:10.1038/s41408-023-00906-7Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 27, 2023 Category: Hematology Authors: Viera Sandecka Tereza Popkova Martin Stork Vladimir Maisnar Jiri Minarik Alexandra Jungova Petr Pavlicek Lukas Stejskal Lenka Pospisilova Adriana Heindorfer Jarmila Obernauerova Evzen Gregora Michal Sykora Jana Ullrychova Marek Wrobel Petr Kessler Tomas J Source Type: research
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Blood Cancer Journal, Published online: 27 September 2023; doi:10.1038/s41408-023-00923-6Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 27, 2023 Category: Hematology Authors: Thomas Martin Meletios-Athanasios Dimopoulos Joseph Mikhael Kwee Yong Marcelo Capra Thierry Facon Roman Hajek Ivan Špička Ross Baker Kihyun Kim Gracia Martinez Chang-Ki Min Ludek Pour Xavier Leleu Albert Oriol Youngil Koh Kenshi Suzuki France Casca Sand Source Type: research
The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
Blood Cancer Journal, Published online: 26 September 2023; doi:10.1038/s41408-023-00920-9The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 26, 2023 Category: Hematology Authors: Saurabh Zanwar Eapen K. Jacob Carl Greiner Kevin Pavelko Michael Strausbauch Emilie Anderson Arini Arsana Megan Weivoda Mithun Vinod Shah Taxiarchis Kourelis Source Type: research
Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group
Blood Cancer Journal, Published online: 26 September 2023; doi:10.1038/s41408-023-00924-5Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 26, 2023 Category: Hematology Authors: Denitza Mironova Chitra M. Saraswati Peter Downie Chow Yee Lai Eleanor Cook Vickyanne Carruthers Perla Moukhaiber Fiona Molloy Joshua Serov Elizabeth McKinnon Frank Alvaro Michael Osborn Tamas Revesz Tim Prestidge Siobhan Cross Caroline M. Bateman Andrew Source Type: research
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Blood Cancer Journal, Published online: 21 September 2023; doi:10.1038/s41408-023-00915-6Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 21, 2023 Category: Hematology Authors: Danielle Hammond Sanam Loghavi Sa A. Wang Marina Y. Konopleva Tapan M. Kadia Naval G. Daver Maro Ohanian Ghayas C. Issa Yesid Alvarado Nicholas J. Short Koji Sasaki Naveen Pemmaraju Guillermo Montalban-Bravo Curtis A. Lachowiez Abhishek Maiti Guillermo Ga Source Type: research
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
Blood Cancer Journal, Published online: 21 September 2023; doi:10.1038/s41408-023-00922-7U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 21, 2023 Category: Hematology Authors: Talha Badar Yenny A. Moreno Vanegas Ahmad Nanaa James M. Foran Aref Al-Kali Abhishek Mangaonkar Hemant Murthy Hassan B. Alkhateeb David Viswanatha Rong He Mithun Shah Cecilia Arana Yi Mark R. Litzow Naseema Gangat Ayalew Tefferi Mrinal M. Patnaik Source Type: research
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management
Blood Cancer Journal, Published online: 19 September 2023; doi:10.1038/s41408-023-00912-9In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 19, 2023 Category: Hematology Authors: Robert M. Rifkin Saulius K. Girnius Stephen J. Noga Ruemu E. Birhiray Suman Kambhampati Sudhir Manda Roger M. Lyons Habte A. Yimer Dasha Cherepanov Eric Lloyd Presley Whidden Joshua Richter Source Type: research
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
Blood Cancer Journal, Published online: 19 September 2023; doi:10.1038/s41408-023-00921-8Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - September 19, 2023 Category: Hematology Authors: Jiang Ji Ziqi Wan Jing Ruan Yuan Yang Qinglin Hu Zesong Chen Chen Yang Miao Chen Bing Han Source Type: research
